KRAS and neoplasm: In parameter group 2, i.e., the morpho-molecular and genetic data (tumor morphology, molecular subtype, and pt53, kras, smad4 and p16 genetics), the tumor morphology did not meet the proportional hazard assumptions and was therefore excluded from the combined analysis.